|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells显示文摘 | Chen Qi Xin Wang Zhirong Shen She Chen Hong Yu Noelle Williams Gelin Wang | 2018 | Cell Research2018，28，5： | 7 |
| 2 | The landscape of aging显示文摘Aging is characterized by a progressive deterioration of physiological integrity,leading to impaired functional ability and ultimately increased susceptibility to death.It is a major risk factor for chronic human diseases,including cardiovascular disease,diabetes,neurological degeneration,and cancer.Therefore,the growing emphasis on “healthy aging” raises a series of important questions in life and social sciences.In recent years,there has been unprecedented progress in aging research,particularly the discovery that the rate of aging is at least partly controlled by evolutionarily conserved genetic pathways and biological processes.In an attempt to bring full-fledged understanding to both the aging process and age-associated diseases,we review the descriptive,conceptual,and interventive aspects of the landscape of aging composed of a number of layers at the cellular,tissue,organ,organ system,and organismal levels. | Yusheng Cai Wei Song Jiaming Li Ying Jing Chuqian Liang Liyuan Zhang Xia Zhang Wenhui Zhang Beibei Liu Yongpan An Jingyi Li Baixue Tang Siyu Pei Xueying Wu Yuxuan Liu Cheng-Le Zhuang Yilin Ying Xuefeng Dou Yu Chen Fu-Hui Xiao Dingfeng Li Ruici Yang Ya Zhao Yang Wang Lihui Wang Yujing Li Shuai Ma Si Wang Xiaoyuan Song Jie Ren Liang Zhang Jun Wang Weiqi Zhang Zhengwei Xie Jing Qu Jianwei Wang Yichuan Xiao Ye Tian Gelin Wang Ping Hu Jing Ye Yu Sun Zhiyong Mao Qing-Peng Kong Qiang Liu Weiguo Zou Xiao-Li Tian Zhi-Xiong Xiao Yong Liu Jun-Ping Liu Moshi Song Jing-Dong J.Han Guang-Hui Liu | 2022 | Science China(Life Sciences)2022，65，12： | 4 |
| 3 | Efficacy,safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants显示文摘A randomized,double-blind,placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a hexavalent live human-bovine reassortant rotavirus vaccine(HRV)against rotavirus gastroenteritis(RVGE).A total of 6400 participants aged 6-12 weeks were enrolled and randomly assigned to either HRV(n?3200)or placebo(n?3200)group.All the subjects received three oral doses of vaccine four weeks apart.The vaccine efficacy(VE)against RVGE caused by rotavirus serotypes contained in HRV was evaluated from 14 days after three doses of administration up until the end of the second rotavirus season.VE against severe RVGE,VE against RVGE hospitalization caused by serotypes contained in HRV,and VE against RVGE,severe RVGE,and RVGE hospitalization caused by natural infection of any serotype of rotavirus were also investigated.All adverse events(AEs)were collected for 30 days after each dose.Serious AEs(SAEs)and intussusception cases were collected during the entire study.Our data showed that VE against RVGE caused by serotypes contained in HRV was 69.21%(95%CI:53.31-79.69).VE against severe RVGE and RVGE hospitalization caused by serotypes contained in HRV were 91.36%(95%CI:78.45-96.53)and 89.21%(95%CI:64.51-96.72)respectively.VE against RVGE,severe RVGE,and RVGE hospitalization caused by natural infection of any serotype of rotavirus were 62.88%(95%CI:49.11-72.92),85.51%(95%CI:72.74-92.30)and 83.68%(95%CI:61.34-93.11).Incidences of AEs from the first dose to one month post the third dose in HRV and placebo groups were comparable.There was no significant difference in incidences of SAEs in HRV and placebo groups.This study shows that this hexavalent reassortant rotavirus vaccine is an effective,well-tolerated,and safe vaccine for Chinese infants. | Zhiwei Wu Qingliang Li Yan Liu Huakun Lv Zhaojun Mo Fangjun Li Qingchuan Yu Fei Jin Wei Chen Yong Zhang Teng Huang Xiaosong Hu Wei Xia Jiamei Gao Haisong Zhou Xuan Bai Yueyue Liu Zhenzhen Liang Zhijun Jiang Yingping Chen Jiuwei Zhang Jialiang Du Biao Yang Bo Xing Yantao Xing Ben Dong Qinghai Yang Chen Shi Tingdong Yan Bo Ruan Haiyun Shi Xingliang Fan Dongyang Feng Weigang Lv Dong Zhang Xiangchu Kong Liuyifan Zhou Dinghong Que Hong Chen Zhongbing Chen Xiang Guo Weiwei Zhou Cong Wu Qingrong Zhou Yuqing Liu Jian Qiao Ying Wang Xinguo Li Kai Duan Yuliang Zhao Gelin Xu Xiaoming Yang | 2022 | Virologica Sinica2022，37，5： | 2 |
| 4 | Association between plasma homocysteine levels and obstructive sleep apnoea in patients with ischaemic stroke显示文摘 | Maogang Chen Bona Wu Xinchun Ye Zhiming Zhou Xuanye Yue Qizhang Wang Wanxiang Wang Yongjun Jiang Xuegan Lian Zhaoyao Chen Gelin Xu Xinfeng Liu | 2011 | Journal of Clinical Neuroscience2011，，11： | 1 |
| 5 | Stereotactic Aspiration Plus Subsequent Thrombolysis for Moderate Thalamic Hemorrhage显示文摘 | Maogang Chen Qizhang Wang Wusheng Zhu Qin Yin Minmin Ma Xinying Fan Yongkun Li Guanzhong Ni Chaolai Liu Wenhua Liu Renliang Zhang Gelin Xu Xinfeng Liu | 2012 | World Neurosurgery2012，，1： | 1 |
| 6 | Genotype analysis of rotaviruses isolated from children during a phase III clinical trial with the hexavalent rotavirus vaccine in China显示文摘The oral hexavalent live human-bovine reassortant rotavirus vaccine(RV6)developed by Wuhan Institute of Biological Products Co.,Ltd(WIBP)has finished a randomized,placebo-controlled phase III clinical trial in four provinces of China in 2021.The trail demonstrated that RV6 has a high vaccine efficacy against the prevalent strains and is safe for use in infants.During the phase III clinical trial(2019–2021),200 rotavirus-positive fecal samples from children with RV gastroenteritis(RVGE)were further studied.Using reverse transcription-polymerase chain reaction and high-throughput sequencing,VP7 and VP4 sequences were obtained and their genetic characteristics,as well as the differences in antigenic epitopes of VP7,were analyzed in detail.Seven rotavirus genotypes were identified.The predominant rotavirus genotype was G9P[8](77.0%),followed by prevalent strains G8P[8](8.0%),G3P[8](3.5%),G3P[9](1.5%),G1P[8](1.0%),G2P[4](1.0%),and G4P[6](1.0%).The amino acid sequence identities of G1,G2,G3,G4,G8,and G9 genotypes of isolates compared to the vaccine strains were 98.8%,98.2%–99.7%,88.4%–99.4%,98.2%,94.2%–100%,and 93.9%–100%,respectively.Notably,the vaccine strains exhibited high similarity in amino acid sequence,with only minor differences in antigenic epitopes compared to the Chinese endemic strains.This supports the potential application of the vaccine in preventing diseases caused by rotaviruses. | Wenqi Zou Qingchuan Yu Yan Liu Qingliang Li Hong Chen Jiamei Gao Chen Shi Ying Wang Wei Chen Xuan Bai Biao Yang Jiuwei Zhang Ben Dong Bo Ruan Liuyifan Zhou Gelin Xu Zhongyu Hu Xiaoming Yang | 2023 | Virologica Sinica2023，38，6： | 0 |
| 7 | Targeting NAD Metabolism for the Therapy of Age-Related Neurodegenerative Diseases显示文摘As the aging population continues to grow rapidly, age-related diseases are becoming an increasing burden on the healthcare system and a major concern for the well-being of elderly individuals. While aging is an inevitable process for all humans, it can be slowed down and age-related diseases can be treated or alleviated. Nicotinamide adenine dinucleotide (NAD) is a critical coenzyme or cofactor that plays a central role in metabolism and is involved in various cellular processes including the maintenance of metabolic homeostasis, post-translational protein modifications, DNA repair, and immune responses. As individuals age, their NAD levels decline, and this decrease has been suggested to be a contributing factor to the development of numerous age-related diseases, such as cancer, diabetes, cardiovascular diseases, and neurodegenerative diseases. In pursuit of healthy aging, researchers have investigated approaches to boost or maintain NAD levels. Here, we provide an overview of NAD metabolism and the role of NAD in age-related diseases and summarize recent progress in the development of strategies that target NAD metabolism for the treatment of age-related diseases, particularly neurodegenerative diseases. | Feifei Li Chou Wu Gelin Wang | 2024 | Neuroscience Bulletin2024，40，2： | 0 |
| 8 | Discovery of small-molecule activators of nicotinamide phosphoribosyltransferase(NAMPT)and their preclinical neuroprotective activity显示文摘The decline of nicotinamide adenine dinucleotide(NAD)occurs in a variety of human pathologies including neurodegeneration.NAD-boosting agents can provide neuroprotective benefits.Here,we report the discovery and development of a class of potent activators(NATs)of nicotinamide phosphoribosyltransferase(NAMPT),the rate-limiting enzyme in the NAD salvage pathway.We obtained the crystal structure of NAMPT in complex with the NAT,which defined the allosteric action of NAT near the enzyme active site.The optimization of NAT further revealed the critical role of K189 residue in boosting NAMPT activity.NATs effectively increased intracellular levels of NAD and induced subsequent metabolic and transcriptional reprogramming.Importantly,NATs exhibited strong neuroprotective efficacy in a mouse model of chemotherapy-induced peripheral neuropathy(CIPN)without any overt toxicity.These findings demonstrate the potential of NATs in the treatment of neurodegenerative diseases or conditions associated with NAD level decline. | Hong Yao Minghui Liu Leibo Wang Yumeng Zu Chou Wu Chenyu Li Ruoxi Zhang Haigen Lu Feifei Li Shuang Xi Shuangquan Chen Xuanyu Gu Tianya Liu Jie Cai Shirong Wang Maojun Yang Guo-Gang Xing Wei Xiong Lan Hua Yefeng Tang Gelin Wang | 2022 | Cell Research2022，32，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员